NCT05430958View on ClinicalTrials.gov

Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2022

Primary Completion Date

March 31, 2024

Study Completion Date

March 31, 2024

Conditions
Coronavirus Infection
Interventions
DRUG

INO-4800

INO-4800 will be given at 0.8 or 1.6 mg for at least 6 months but no more than 12 months following the completion of a primary vaccination.

DRUG

INO-9112

INO-9112 will be given in at various doses (dose of 0, 0.05, 0.10, 0.20 or 0.40 mg) in combination with INO-4800.

DEVICE

CELLECTRA® 2000

Electroporation (EP) using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800.

Sponsors
All Listed Sponsors
lead

Inovio Pharmaceuticals

INDUSTRY

NCT05430958 - Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers | Biotech Hunter | Biotech Hunter